{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:46:40Z","timestamp":1792680400437,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100022502","name":"Mereo BioPharma","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100022502","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Osteogenesis imperfecta (OI) is a heritable skeletal disorder and comprises various subtypes that differ in clinical presentation, with Type I considered the least severe and Types III\/IV the most severe forms. The study aim was to understand the OI patient diagnostic and treatment journey across Europe.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted a qualitative, descriptive study to understand the OI patient journey. A selection of people with OI\/their caregivers and clinicians involved in OI-patient care from across Europe were interviewed using a specially developed questionnaire.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Between May 2022 and July 2022, 22 people with OI\/caregivers and 22 clinicians (endocrinologists, orthopaedic surgeons, geneticists and metabolic specialists) from across Europe were interviewed. Our study showed various areas of concerns for the OI community. Timely diagnosis of OI is essential; misdiagnoses and a delay to treatment initiation are all too common. There are a lack of consensus guidelines regarding optimal treatments (including when bisphosphonate therapy should be initiated and the route of administration) and patient management throughout the duration of the patient\u2019s life. Adult OI patients do not have a medical home and are often managed by endocrinologists and rheumatologists. Adult care is often reactive based on the development of new symptoms. The psychosocial burden of OI impacts on the patient\u2019s quality of life.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>There is an urgent need for increased awareness about OI and its wide range of symptoms. In particular, there is a need for consensus guidelines outlining the optimum care throughout the duration of the OI patient\u2019s life.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-024-03345-0","type":"journal-article","created":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T14:03:34Z","timestamp":1725890614000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Osteogenesis Imperfecta: A study of the patient journey in 13 European countries"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2839-9856","authenticated-orcid":false,"given":"Ingunn","family":"Westerheim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Cormier-Daire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"O\u2019Malley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Keen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,9]]},"reference":[{"key":"3345_CR1","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.bone.2017.02.004","volume":"102","author":"J Lim","year":"2017","unstructured":"Lim J, Grafe I, Alexander S, Lee B. Genetic causes and mechanisms of Osteogenesis Imperfecta. Bone. 2017;102:40\u20139.","journal-title":"Bone"},{"issue":"5","key":"3345_CR2","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1002\/ajmg.a.63132","volume":"191","author":"S Unger","year":"2023","unstructured":"Unger S, Ferreira CR, Mortier GR, Ali H, Bertola DR, Calder A, et al. Nosology of genetic skeletal disorders: 2023 revision. Am J Med Genet A. 2023;191(5):1164\u2013209.","journal-title":"Am J Med Genet A"},{"issue":"1","key":"3345_CR3","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/s13023-023-02849-5","volume":"18","author":"H Yu","year":"2023","unstructured":"Yu H, Li C, Wu H, Xia W, Wang Y, Zhao J, Xu C. Pathogenic mechanisms of osteogenesis imperfecta, evidence for classification. Orphanet J Rare Dis. 2023;18(1):234.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3345_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40246-017-0115-5","volume":"11","author":"L Zhytnik","year":"2017","unstructured":"Zhytnik L, Maasalu K, Reimann E, Prans E, Koks S, Martson A. Mutational analysis of COL1A1 and COL1A2 genes among Estonian osteogenesis imperfecta patients. Hum Genomics. 2017;11(1):19.","journal-title":"Hum Genomics"},{"issue":"1","key":"3345_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/ejhg.2011.141","volume":"20","author":"FS van Dijk","year":"2012","unstructured":"van Dijk FS, Byers PH, Dalgleish R, Malfait F, Maugeri A, Rohrbach M, et al. EMQN best practice guidelines for the laboratory diagnosis of osteogenesis imperfecta. Eur J Hum Genet. 2012;20(1):11\u20139.","journal-title":"Eur J Hum Genet"},{"issue":"2","key":"3345_CR6","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1136\/jmg.16.2.101","volume":"16","author":"DO Sillence","year":"1979","unstructured":"Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet. 1979;16(2):101\u201316.","journal-title":"J Med Genet"},{"key":"3345_CR7","unstructured":"Marini JC, Dang Do AN. Osteogenesis Imperfecta. [Updated 2020 Jul 26]. Endotext [Internet]: South Dartmouth (MA): MDText.com, Inc.; 2000-. ; 2020. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK279109\/"},{"issue":"8","key":"3345_CR8","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/ejhg.2015.81","volume":"23","author":"K Lindahl","year":"2015","unstructured":"Lindahl K, Astrom E, Rubin CJ, Grigelioniene G, Malmgren B, Ljunggren O, Kindmark A. Genetic epidemiology, prevalence, and genotype-phenotype correlations in the Swedish population with osteogenesis imperfecta. Eur J Hum Genet. 2015;23(8):1042\u201350.","journal-title":"Eur J Hum Genet"},{"issue":"6","key":"3345_CR9","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1002\/ajmg.a.36545","volume":"164A","author":"FS Van Dijk","year":"2014","unstructured":"Van Dijk FS, Sillence DO. Osteogenesis Imperfecta: clinical diagnosis, nomenclature and severity assessment. Am J Med Genet A. 2014;164A(6):1470\u201381.","journal-title":"Am J Med Genet A"},{"issue":"6","key":"3345_CR10","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1097\/GIM.0b013e3181a1ff7b","volume":"11","author":"D Basel","year":"2009","unstructured":"Basel D, Steiner RD. Osteogenesis Imperfecta: recent findings shed new light on this once well-understood condition. Genet Med. 2009;11(6):375\u201385.","journal-title":"Genet Med"},{"issue":"9418","key":"3345_CR11","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1016\/S0140-6736(04)16051-0","volume":"363","author":"F Rauch","year":"2004","unstructured":"Rauch F, Glorieux FH. Osteogenesis Imperfecta. Lancet. 2004;363(9418):1377\u201385.","journal-title":"Lancet"},{"key":"3345_CR12","unstructured":"Commisssion E. Rare diseases: EU research on rare diseases [https:\/\/research-and-innovation.ec.europa.eu\/research-area\/health\/rare-diseases_en"},{"key":"3345_CR13","unstructured":"Administration FaD. 2022 [ https:\/\/www.fda.gov\/science-research\/focus-areas-regulatory-science-report\/cross-cutting-topics-rare-diseases-regulatory-science-research#:~:text=A%20rare%20disease%20is%20defined,recovery%20provisions%20of%20the%20act"},{"key":"3345_CR14","doi-asserted-by":"publisher","first-page":"924","DOI":"10.3389\/fendo.2019.00924","volume":"10","author":"SH Ralston","year":"2019","unstructured":"Ralston SH, Gaston MS. Management of Osteogenesis Imperfecta. Front Endocrinol (Lausanne). 2019;10:924.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3345_CR15","first-page":"367","volume":"6","author":"E Monti","year":"2010","unstructured":"Monti E, Mottes M, Fraschini P, Brunelli P, Forlino A, Venturi G, et al. Current and emerging treatments for the management of osteogenesis imperfecta. Ther Clin Risk Manag. 2010;6:367\u201381.","journal-title":"Ther Clin Risk Manag"},{"key":"3345_CR16","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.3389\/fphar.2019.01200","volume":"10","author":"J Shi","year":"2019","unstructured":"Shi J, Ren M, Jia J, Tang M, Guo Y, Ni X, Shi T. Genotype-Phenotype Association Analysis Reveals New Pathogenic Factors for Osteogenesis Imperfecta Disease. Front Pharmacol. 2019;10:1200.","journal-title":"Front Pharmacol"},{"issue":"6","key":"3345_CR17","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.3892\/etm.2014.1653","volume":"7","author":"J Ren","year":"2014","unstructured":"Ren J, Xu X, Jian X, Wang J. Osteogenesis imperfecta type I: a case report. Exp Ther Med. 2014;7(6):1535\u20138.","journal-title":"Exp Ther Med"},{"issue":"12","key":"3345_CR18","doi-asserted-by":"publisher","first-page":"e15924","DOI":"10.2196\/15924","volume":"21","author":"AR Castro","year":"2019","unstructured":"Castro AR, Chougui K, Bilodeau C, Tsimicalis A. Exploring the views of Osteogenesis Imperfecta Caregivers on Internet-Based technologies: qualitative descriptive study. J Med Internet Res. 2019;21(12):e15924.","journal-title":"J Med Internet Res"},{"issue":"1","key":"3345_CR19","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13023-023-02627-3","volume":"18","author":"M Rapoport","year":"2023","unstructured":"Rapoport M, Bober MB, Raggio C, Wekre LL, Rauch F, Westerheim I, et al. The patient clinical journey and socioeconomic impact of osteogenesis imperfecta: a systematic scoping review. Orphanet J Rare Dis. 2023;18(1):34.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"3345_CR20","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.chest.2017.12.018","volume":"153","author":"JK Stoller","year":"2018","unstructured":"Stoller JK. The challenge of Rare diseases. Chest. 2018;153(6):1309\u201314.","journal-title":"Chest"},{"issue":"9","key":"3345_CR21","doi-asserted-by":"publisher","first-page":"e060394","DOI":"10.1136\/bmjopen-2021-060394","volume":"12","author":"JC Long","year":"2022","unstructured":"Long JC, Best S, Nic Giolla Easpaig B, Hatem S, Fehlberg Z, Christodoulou J, Braithwaite J. Needs of people with rare diseases that can be supported by electronic resources: a scoping review. BMJ Open. 2022;12(9):e060394.","journal-title":"BMJ Open"},{"issue":"10","key":"3345_CR22","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/nrg3555","volume":"14","author":"KM Boycott","year":"2013","unstructured":"Boycott KM, Vanstone MR, Bulman DE, MacKenzie AE. Rare-disease genetics in the era of next-generation sequencing: discovery to translation. Nat Rev Genet. 2013;14(10):681\u201391.","journal-title":"Nat Rev Genet"},{"key":"3345_CR23","unstructured":"Global Genes. RARE disease facts: Global Genes; 2023 [https:\/\/globalgenes.org\/learn\/rare-disease-facts\/"},{"issue":"1","key":"3345_CR24","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13023-019-1285-0","volume":"15","author":"E Ramalle-Gomara","year":"2020","unstructured":"Ramalle-Gomara E, Dominguez-Garrido E, Gomez-Eguilaz M, Marzo-Sola ME, Ramon-Trapero JL, Gil-de-Gomez J. Education and information needs for physicians about rare diseases in Spain. Orphanet J Rare Dis. 2020;15(1):18.","journal-title":"Orphanet J Rare Dis"},{"key":"3345_CR25","doi-asserted-by":"publisher","first-page":"734601","DOI":"10.3389\/fphar.2021.734601","volume":"12","author":"PE Chazal","year":"2021","unstructured":"Chazal PE, Aym\u00e9 S. An Objective Approach to identify Priority Rare diseases for the development of solutions reducing the Diagnostic Delay based on French Data. Front Pharmacol. 2021;12:734601.","journal-title":"Front Pharmacol"},{"key":"3345_CR26","doi-asserted-by":"crossref","unstructured":"Adachi T, El-Hattab AW, Jain R, Nogales Crespo KA, Quirland Lazo CI, Scarpa M et al. Enhancing Equitable Access to Rare Disease diagnosis and treatment around the World: a review of evidence, policies, and challenges. Int J Environ Res Public Health. 2023;20(6).","DOI":"10.3390\/ijerph20064732"},{"issue":"3","key":"3345_CR27","doi-asserted-by":"publisher","first-page":"123","DOI":"10.4103\/picr.picr_193_21","volume":"13","author":"S Thakur","year":"2022","unstructured":"Thakur S. Advances in orphan drug development: time to change the status and stereotype. Perspect Clin Res. 2022;13(3):123\u20138.","journal-title":"Perspect Clin Res"},{"issue":"10","key":"3345_CR28","doi-asserted-by":"publisher","first-page":"e0140002","DOI":"10.1371\/journal.pone.0140002","volume":"10","author":"T Gammie","year":"2015","unstructured":"Gammie T, Lu CY, Babar ZU. Access to Orphan drugs: a Comprehensive Review of legislations, regulations and policies in 35 countries. PLoS ONE. 2015;10(10):e0140002.","journal-title":"PLoS ONE"},{"issue":"1","key":"3345_CR29","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1186\/s13023-021-01939-6","volume":"16","author":"JC Long","year":"2021","unstructured":"Long JC, Best S, Hatem S, Theodorou T, Catton T, Murray S, et al. The long and winding road: perspectives of people and parents of children with mitochondrial conditions negotiating management after diagnosis. Orphanet J Rare Dis. 2021;16(1):310.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"3345_CR30","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/ANS.0000000000000263","volume":"42","author":"M Beauchemin","year":"2019","unstructured":"Beauchemin M, Cohn E, Shelton RC. Implementation of clinical practice guidelines in the Health Care setting: a Concept Analysis. ANS Adv Nurs Sci. 2019;42(4):307\u201324.","journal-title":"ANS Adv Nurs Sci"},{"key":"3345_CR31","first-page":"399","volume":"62","author":"KD Baldwin","year":"2013","unstructured":"Baldwin KD, Scherl SA. Orthopaedic aspects of child abuse. Instr Course Lect. 2013;62:399\u2013403.","journal-title":"Instr Course Lect"},{"issue":"1","key":"3345_CR32","first-page":"e12790","volume":"13","author":"A Altalib","year":"2021","unstructured":"Altalib A, Althomali A, Alshahrani A, Alfrayyan A, Aljughaiman MS. Osteogenesis Imperfecta and child abuse from a forensic point of View. Cureus. 2021;13(1):e12790.","journal-title":"Cureus"},{"key":"3345_CR33","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/1471-2431-13-153","volume":"13","author":"MJ Dogba","year":"2013","unstructured":"Dogba MJ, Bedos C, Durigova M, Montpetit K, Wong T, Glorieux FH, Rauch F. The impact of severe osteogenesis imperfecta on the lives of young patients and their parents - a qualitative analysis. BMC Pediatr. 2013;13:153.","journal-title":"BMC Pediatr"},{"key":"3345_CR34","doi-asserted-by":"crossref","unstructured":"Botor M, Fus-Kujawa A, Uroczynska M, Stepien KL, Galicka A, Gawron K, Sieron AL. Osteogenesis Imperfecta: current and prospective therapies. Biomolecules. 2021;11(10).","DOI":"10.3390\/biom11101493"},{"issue":"10","key":"3345_CR35","first-page":"CD005088","volume":"10","author":"K Dwan","year":"2016","unstructured":"Dwan K, Phillipi CA, Steiner RD, Basel D. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev. 2016;10(10):CD005088.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"3345_CR36","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s13023-023-02856-6","volume":"18","author":"E Casado","year":"2023","unstructured":"Casado E, G\u00f3mez-Alonso C, Pintos-Morell G, Bou-Torrent R, Barreda-Bonis AC, Torregrosa JV, et al. Transition of patients with metabolic bone disease from paediatric to adult healthcare services: current situation and proposals for improvement. Orphanet J Rare Dis. 2023;18(1):245.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3345_CR37","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13023-022-02232-w","volume":"17","author":"D Genevaz","year":"2022","unstructured":"Genevaz D, Arnoux A, Marcel C, Brassier A, Pichard S, Feillet F, et al. Transition from child to adult health care for patients with lysosomal storage diseases in France: current status and priorities-the TENALYS study, a patient perspective survey. Orphanet J Rare Dis. 2022;17(1):68.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3345_CR38","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13023-023-02698-2","volume":"18","author":"C Grasemann","year":"2023","unstructured":"Grasemann C, Hoppner J, Burgard P, Schundeln MM, Matar N, Muller G, et al. Transition for adolescents with a rare disease: results of a nationwide German project. Orphanet J Rare Dis. 2023;18(1):93.","journal-title":"Orphanet J Rare Dis"},{"key":"3345_CR39","doi-asserted-by":"publisher","first-page":"263300402311644","DOI":"10.1177\/26330040231164425","volume":"4","author":"AM Patterson","year":"2023","unstructured":"Patterson AM, O\u2019Boyle M, VanNoy GE, Dies KA. Emerging roles and opportunities for rare disease patient advocacy groups. Ther Adv Rare Dis. 2023;4:26330040231164425.","journal-title":"Ther Adv Rare Dis"},{"issue":"40","key":"3345_CR40","doi-asserted-by":"publisher","first-page":"e30256","DOI":"10.1097\/MD.0000000000030256","volume":"101","author":"R Munoz Cortes","year":"2022","unstructured":"Munoz Cortes R, Soriano Pastor JF, Monsalve Dolz V. Chronic pain in adults with osteogenesis imperfecta and its relationship to appraisal, coping, and quality of life: a cross-sectional study. Med (Baltim). 2022;101(40):e30256.","journal-title":"Med (Baltim)"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03345-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-024-03345-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03345-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T14:06:23Z","timestamp":1725890783000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-024-03345-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,9]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3345"],"URL":"https:\/\/doi.org\/10.1186\/s13023-024-03345-0","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,9]]},"assertion":[{"value":"2 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval for the study was not required. Written informed consent was obtained from each patient interviewed for the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from each patient interviewed for the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"IW is President of OIFE, which has received conference grants and donations from Mereo BioPharma, Ultragenyx, Quince Therapeutics, UCB, Angitian Bio, Azafaros, Alexion and Pega Medica and Orthopediatrics. IW is a member of a steering committee at Sanofi and has received speaker funding from Takeda. VCD is the principal investigator in a clinical trial funded by Mereo BioPharma and Ultragenyx. SG and SOM were paid by Mereo Biopharma to complete the market research used in this publication. RK is a consultant for Mereo Biopharma and has a voluntary (unpaid) role as the Chair of the Brittle Bone Society Scientific Committee, Dundee, UK. IW, VCD and RK received no specific payment associated with the development of this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"331"}}